ONCO News
Archived Headlines
- Updated: Renaissance Capital's 1Q 2022 US IPO Market Review 04/01/22
- Sector-wide sell-off: IPOs from all but one sector have traded off in recent months 03/17/22
- Renaissance Capital's February IPO Market Update 03/01/22
- US IPO Weekly Recap: The IPO market's micro-cap run continues with 2 small healthcare deals 02/18/22
- Vaccine biotech Blue Water Vaccines prices IPO at $9 midpoint 02/18/22
See more
2022 IPOs with the largest first-day pops are now some of the worst performers
So far in 2022, IPO activity has been dominated by small, volatile issuers. Of the year’s 51 pricings to date, 19 (37%) have soared 100% or more in their debuts, while one-in-ten have jumped at least 500%. But those with the largest first-day pops have...read more
Tiny takeover: Small issuers account for over 60% of 2022 IPO activity
Companies have broadly put listing plans on hold amid the worst IPO sell-off in over a decade, but small issuers are still on the move. So far, 21 of the year’s 34 IPOs (62%) have raised less than $50 million, the highest concentration in over a decade....read more
Biotech IPOs struggle to tread water amid challenging market conditions
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
Pop and drop: Micro-cap IPOs with the best first-day pops of 2022 plummet in the aftermarket
Since the start of the year, three small IPOs have popped more than 400%. The gains proved to be short-lived, however: All three high-flyers have plummeted in the aftermarket and now average a -29% return from IPO. Last week, Singapore-based ...read more